Methods for inhibiting muscle atrophy

Patent metadata

Field	Value
Publication number	US-9856204-B2
Application number	US-201113698645-A
Country	US
Kind code	B2
Filing date	May 19, 2011
Priority date	May 20, 2010
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

First claim

What is claimed is:

1. A method for increasing skeletal muscle mass in an animal, the method comprising administering to the animal ursolic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein said animal is selected from the group consisting of a primate, domesticated fish, domesticated crustacean, domesticated mollusk, poultry, rabbit, dog, cat, and livestock.

2. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than or equal to 100 mg per day.

3. The method of claim 1 , wherein the animal is a mammal.

4. The method of claim 1 , wherein the animal is a human.

5. The method of claim 1 , wherein the animal is selected from the group consisting of a dog, cat, pig, cow, horse, goat, bison, sheep, chicken, turkey, duck, goose, and domesticated fish.

6. The method of claim 1 , wherein the ursolic acid is present as a pharmaceutically acceptable salt selected from salts derived from aluminum, ammonium, calcium, copper (-ic and -ous), ferric, ferrous, lithium, magnesium, manganese, potassium, sodium, or zinc; salts of primary, secondary, and tertiary amines; and salts derived from arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholinc, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, or tromethamine.

7. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than 200 mg per day.

8. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than 300 mg per day.

9. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than 400 mg per day.

10. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than 500 mg per day.

11. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than 750 mg per day.

12. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than 1000 mg per day.

13. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in composition that further comprises one or more adjuvants.

14. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in a dosage of from about 0.1 to about 50 mg/kg per day.

15. The method of claim 4 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in a dosage of from about 0.1 to about 50 mg/kg per day.

16. The method of claim 7 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in a dosage of from about 0.1 to about 50 mg/kg per day.

17. The method of claim 1 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in a composition that further comprises a preservative.

18. The method of claim 17 , wherein the ursolic acid or pharmaceutically acceptable salt, hydrate, or solvate thereof is administered to the animal in an amount of greater than or equal to 2100 mg per day.

19. The method of claim 17 , wherein the animal is selected from a domesticated fish, poultry, pig, cow, horse, goat, bison, sheep, dog, cat, and bison.

20. The method of claim 18 , wherein the animal is selected from a domesticated fish, poultry, pig, cow, horse, goat, bison, sheep, dog, cat, and bison.

Assignees

• Adams Christopher M
• Kunkel Steven D
• Suneja Manish
• Welsh Michael
• Univ Iowa Res Found
• The United States Of America As Represented By Veterans Affairs

Inventors

• Adams Christopher M
• Kunkel Steven D
• Suneja Manish
• Welsh Michael

Classifications

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• C07D265/30

  not condensed with other rings · CPC title

• C07C69/757

  having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] in the acid moiety · CPC title

• C07C61/29 Primary

  having a carboxyl group bound to a condensed ring system · CPC title

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title